Plasmid-Encoded Proinsulin Preserves C-Peptide While Specifically Reducing Proinsulin-Specific CD8( ) T Cells in Type 1 Diabetes
Bart O Roep, Nanette Solvason, Peter A Gottlieb, Joana RF Abreu, Leonard C Harrison, George S Eisenbarth, Liping Yu, Michael Leviten, William A Hagopian, John B Buse, Matthias von Herrath, Joanne Quan, Robert S King, William H Robinson, Paul J Utz, Hideki Garren, Lawrence Steinman
SCIENCE TRANSLATIONAL MEDICINE | AMER ASSOC ADVANCEMENT SCIENCE | Published : 2013
In type 1 diabetes (T1D), there is an intense inflammatory response that destroys the β cells in the pancreatic islets of Langerhans, the site where insulin is produced and released. A therapy for T1D that targets the specific autoimmune response in this disease while leaving the remainder of the immune system intact, has long been sought. Proinsulin is a major target of the adaptive immune response in T1D. We hypothesized that an engineered DNA plasmid encoding proinsulin (BHT-3021) would preserve β cell function in T1D patients through reduction of insulin-specific CD8⁺ T cells. We studied 80 subjects over 18 years of age who were diagnosed with T1D within the past 5 years. Subjects were r..View full abstract
Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
Funding: This work was supported by Bayhill Therapeutics.